Key facts about
Innovation in the field of metabolic disease
By 2040 more than 640 million people impacted of which ~90% have T2 diabetes.
Scientist founders are international experts of the gut-brain axis
Internationally acknowledged in the field of microbiota and gut-brain axis in the control of glycemia.
Orally deliverable peptides
An upstream regulator of glycaemia leading to systemic physiological effect. A local effect for a remote control strategy.
Identification through validated OMICS strategies of innovative therapeutic peptides and targets.